CONGRESS PRESENTATIONS
CROI 2026
Denver, Colorado
Feb 22-25, 2026
-
ViiV-Sponsored Data
-
Cabotegravir Prevention
Barnett S, et al.
Comparing PrEP coverage and HIV acquisition between CAB LA and oral PrEP in the OPERA cohort
Elion R, et al.
Long term use, HIV testing and effectiveness in individuals on CAB LA PrEP in the Trio Health Cohort
Fox D, et al.
Injection Site Reactions More Common and Bothersome with Single Doses of Lenacapavir vs Cabotegravir
Hsu RK, et al.
Cabotegravir LA for PrEP: Progress in HIV Prevention from Three Years of OPERA Data
Jones J, et al.
Trends in Long-Acting PrEP Awareness, Willingness to Use, and Uptake among Men Who Have Sex with Men in the United States: Serial Cross-Sectional Study, 2021-2023
Metzner AA, et al.
Adherence and Persistence in US Real-World New PrEP Users: Cabotegravir (CAB-LA) vs Oral PrEP
Metzner AA, et al.
Preventive Care in US Real-World Cabotegravir (CAB-LA) for Pre-exposure Prophylaxis (PrEP) Users
Tims-Cook Z, et al.
EBONI M12 Results: High Real-World Effectiveness and Acceptance of CAB LA for PrEP in Black Women
-
Cabotegravir Treatment
Dieterich DT, et al.
HIV-HBV Coinfection and Long-Acting Cabotegravir + Rilpivirine in the US: HBV and HIV Outcomes
Hsu RK, et al.
Outcomes for Individuals who Initiate CAB+RPV LA in OPERA with Viral Loads ≥50 vs. <50 copies/mL
Rolle C-P, et al.
Early Switch to CAB+RPV LA in Treatment-Naive Adults With HIV-1: Month 11 Outcomes From VOLITION
Sension MG, et al.
Body Mass Index and Virologic Outcomes in Individuals on CAB+RPV LA in the OPERA Cohort
-
Dolutegravir-based Regimens
Anderson K, et al.
Viral Suppression with Dolutegravir-Based Regimens in Children ≤5 Years Old in Southern Africa
Cahn P, et al.
Meta-analysis of DTG/3TC vs DTG 3DRs In ART-Naïve People with High Baseline Viral Loads and Low CD4+
Surial B, et al.
Evaluating the impact of integrase inhibitors (INSTIs) on cardiovascular disease (CVD)
-
Pipeline
Castronova E, et al.
Dose Selection of Ultra-Long-Acting Cabotegravir as HIV-1 Pre-Exposure Prophylaxis: A Phase 1 Study
Thakkar N, et al.
Population PK and Exposure-Response Analysis of Orally Administered VH4011499 in people living with HIV-1
Underwood M, et al.
Third-Generation INSTI VH4524184 (VH-184) Has an Enhanced Resistance Profile vs Bictegravir
-
-
ViiV-Supported & Collaborative Data
-
Cabotegravir Prevention
Chi KK, et al.
Cost-effectiveness of HIV monitoring for long-acting cabotegravir pre-exposure prophylaxis in the US
Ford SL, et al.
Population PK Modelling and Simulation Suggests CAB LA Dose Adjustment not Required in Pregnancy
Marzinke MA, et al.
Assessment of Total and Unbound Cabotegravir Pharmacokinetics Among Pregnant Women in HPTN 084
Parikh UM, et al.
Characterization of HIV Acquisitions on Long-Acting Cabotegravir PrEP from ImPrEP CAB Brasil
Stansfield SE, et al.
Modeled Effectiveness of CAB-LA Prioritization Strategies Based on Data from HPTN 083
Whitlock G, et al.
Prevalence and patterns of prior PrEP use and discontinuation in individuals newly diagnosed with HIV infection at 56 Dean Street, London, UK: 2017-2024
-
Cabotegravir Treatment
Archary M, et al.
Safety And Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Young Children 10 - <40kg
Dieterich M, et al.
At-Home CAB+RPV LA Delivery Yields Durable 10-Month Persistence, Viral Suppression, and Improved Adherence in PWH with Adherence Challenges
Hernandez-Sanchez D, et al.
High Acceptability and Safety of Out-of-Hospital Administration of Long-Acting Cabotegravir and Rilpivirine: HOLA Study
Morelli MK, et al.
Insight from PWH: A Roadmap to New Models for Long-Acting Injectable Antiretroviral Administration
-
Dolutegravir-based Regimens
Brites C, et al.
Discontinuation of dolutegravir therapy due to any drug-related event among PLVHIV in Brazil
Domingo P, et al.
Transcriptomic Changes in Adipose Tissue of People with HIV on BIC/FTC/TAF or DTG/3TC Treatment
Esteban-Cantos A, et al.
CD4/CD8 T Cell Telomere Length at 96 Weeks in the PASO-DOBLE Trial Comparing BIC/FTC/TAF and DTG/3TC
Korutaro V, et al.
Maternal and Infant Predictors of Mortality in Liveborn Infants in the IMPAACT 2010 (VESTED) Trial
McCluskey SM, et al.
Validity of point-of-care urine tenofovir testing to detect viral suppression on TLD
Ombajo LA, et al.
Efficacy and safety of switching to DTG/3TC dual therapy from B/F/TAF among older adults ≥60 years
Pineda JA, et al.
Effect of DTG/3TC vs. BIC/FTC/TAF on Steatotic Liver Disease: 96-week Analysis of PASO-DOBLE Trial
Pintye J, et al.
In utero transfer of dolutegravir and efavirenz assessed via hair levels in IMPAACT 2010 trial
Rosen EP, et al.
First-Line DTG+3TC Effectively Reaches and Reduces HIV in Lymph Node Reservoirs
-
Other Disease-Related Content
Chan P, et al.
Endothelial and Hemostasis Perturbations During Acute HIV Infection and After Immediate Therapy
Chan P, et al.
Neuropsychiatric Changes in People with HIV With or Without Long COVID After SARS-CoV-2 Infection
Chavez JV, et al.
Proteomic Correlates of Depressive Symptom Clusters: Insights from the RV254/SEARCH010 Acute HIV Cohort in Thailand
Del Rio Estrada PM, et al.
BCL6 Enhances Tfh Cells Susceptible to HIV Infection by Dampening Intrinsic Antiviral Machineries
Delporte M, et al.
HIV Reservoir Size Relates To Comorbidities In People With HIV On Long Term Antiretroviral Therapy
Holroyd KB, et al.
Long-Term Neurologic Exam Findings in People Diagnosed and Treated During Acute HIV Infection
Huber A, et al.
IL-32 Expression and Genetic Regulation Associate With Persistent HIV Control
Knoll R, et al.
Single-cell Multi-Omics Reveals Systemic Immune Aging Acceleration in People Living with HIV
Martinez E, et al.
Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect and Cardiovascular Consequences
Mehta K, et al.
CXCR4-tropic HIV-1 shapes unique immunopathology and larger reservoir
Navas A, et al.
PD-1 expression on PBMCs in PLHIV mainly influences CD4+-lymphocyte functionality
Paul R, et al.
Machine learning-derived cognitive subtypes of HIV: Results from the NIMH MIAAD-NHIV initiative
Ruijten SDE, et al.
HIV-Associated Sex Differences in the Plasma Proteome Associate with Reservoir Size and CVD
Ruijten SDE, et al.
Increased Interferon Signaling in Immunological Non-Responders is Linked to anti-CMV and anti-EBV IgG
Sacdalan C, et al.
RV550: Analytic Treatment Interruption after N-803 in Participants on ART since Acute HIV
Schwab SK, et al.
Differences in virologic suppression by TFV-DP in DBS and TAF regimen: results from ACTG A5359
Smith ED, et al.
Characterization of Heterogeneous Statin Benefit in REPRIEVE to Inform Prevention
Sofie DB, et al.
High-Throughput HIV-1 Reservoir Mapping: Intactness, Drug Resistance and Immune Therapy Predictions
Suarez-Zdunek MA, et al.
Cytomegalovirus Antibody Concentrations and Cardiovascular Disease Risk in People with and Without HIV
Sukumaran L, et al.
Associations between CMV IgG concentrations and multimorbidity burden in people living with HIV in the POPPY Study
Sukumaran L, et al.
Associations of inflammatory biomarkers with cardiovascular disease burden and predicted risk in people with HIV
Umbleja T, et al.
Pitavastatin Effects on Lipids in Relation to MACE: a REPRIEVE Secondary Analysis
Wang J, et al.
Single-Cell Multiomics Reveals ART-Induced Naïve CD8+ T Cell Remodeling Predicts Delayed HIV Rebound
Wright V, et al.
Depression and Inflammation in Acute HIV: An RDoC-Based PHQ-9 Factor Analysis
Zhao S, et al.
Cancer Incidence and Risk Factors Among People with HIV in REPRIEVE
-
Pipeline
-
